What Happened?
Redwood City, California-based Heron Therapeutics Inc Appointed Nancy Knochel Clodfelter as Human Resources Director
About the Company
Heron Therapeutics, Inc. (Heron) focuses on the development of novel, patient-focused therapeutic products using its proprietary Biochronomer polymer-based drug delivery technology. It designs and commercializes Biochronomer polymer technologies for pharmaceutical and other applications. Biochronomer is a polymer-based proprietary drug delivery platform that consists of bio-erodible polymers designed to release drugs over a defined period of time. The platform improves the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. Biochronomer technology can be designed to deliver drugs over periods varying from days to several months.The company has a pipeline of three products, namely, the lead product candidate Sustol| HTX-011| and HTX-019 on the basis of its proprietary Biochronomer technology.Herons lead product candidate Sustol (formerly APF530) is an injection under development for the prevention of both delayed-onset and acute-onset chemotherapy-induced nausea and vomiting (CINV). Sustol contains the 5-HT3 receptor antagonist granisetron formulated by its Biochronomer technology, which prevents CINV for at least five days with a single subcutaneous injection. Injectable and oral formulations of granisetron are approved only for the treatment of acute-onset CINV. The company submitted the NDA application in 2015. NDA for Sustol is pending review with the US FDA.The companys other pipeline drug includes HTX-011 for the management of post-operative pain. HTX-011 is a non-opioid, sustained-release product and is a combination of local anesthetic bupivacaine and anti-inflammatory Meloxicam. This drug is formulated by utilizing Biochronomer technology to release drug for up to 72 hours. In September 2015, Heron reported positive, top-line results from a randomized, placebo-controlled, double-blind, Phase II clinical trial of HTX-011 in patients undergoing bunionectomy. In February 2016, the company initiated a placebo-controlled, dose-finding, Phase II clinical trial of HTX-011. The company plans to further develop HTX-011 within a broad-based development program targeting the broad range of surgical procedures with significant potential for post-operative pain.Herons other preclinical pipeline product HTX-019 ((NK1 Receptor Antagonist) is being developed for the prevention of CINV. HTX-019 is an injectable formulation of NK receptor antagonist used in combination with 5-HT receptor antagonists. The company intends to file an NDA for HTX-019 in the second half of 2016.Heron focuses its research and development (R&|D) activities on the development and commercialization of its product pipeline. In FY2015, the company reported R&|D expenses of US$61.18 million, as compared to that of US$54.83 million in FY2014.
About the Person
Nancy Knochel Clodfelter is Human Resources Director at Heron Therapeutics Inc. Previously, Nancy held various senior HR leadership roles in the industry.
Info Source
News
Short Profile